| Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). | |
| | |
MedLine Citation:
|
PMID: 21585408 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Background Somatostatin analogues are the mainstay of therapy for malignant carcinoid syndrome. There is clear evidence that the once monthly intramuscular formulation, Octreotide LAR, controls symptoms of carcinoid syndrome, and recent data also suggests an antitumour effect. There is limited data on prolonged release Lanreotide (Somatuline Autogel, Ipsen Pharma Biotech, Signes, France) and no long-term data to date. Aim To present long-term results of prolonged release Lanreotide in a large cohort of patients with malignant carcinoid syndrome, assessing clinical and objective response and tolerance. Methods Seventy six patients with metastatic midgut neuroendocrine tumours and carcinoid syndrome were included in this 9-year retrospective study. Clinical response was based on symptom score with radiological assessment based on RECIST (Response Evaluation Criteria In Solid Tumours). Results Data were available in 69 patients. Ninety four percent achieved symptomatic response at first follow-up visit. Forty six percent had loss of symptomatic response, but 44% of these achieved control with an increase in dose of prolonged release Lanreotide. Overall, symptoms were well controlled throughout the study period with prolonged release Lanreotide alone in 74% of patients. Twenty six percent required additional treatment despite good initial response. Only 30% demonstrated radiological progression. Eleven patients who were switched from Octreotide LAR had return of symptomatic control. No significant adverse effects were experienced. Conclusions Prolonged release Lanreotide provides good symptomatic control of diarrhoea and flushing as well as tumour stability in patients with malignant carcinoid syndrome. |
| | |
Authors:
|
M S Khan; F El-Khouly; P Davies; C Toumpanakis; M E Caplin |
Related Documents
:
|
19609148 - The hoarding syndrome: screening and treatment. 19875968 - Successful treatment of retroperitoneal infantile hemangioendothelioma with kasabach-me... 15636438 - Is ovulation induction still a therapeutic problem in patients with polycystic ovary sy... 11393578 - Clinical, endocrinological and radiography features in a child with mccune-albright syn... 1669958 - Successful treatment of kasabach-merritt syndrome with prednisone and epsilon-aminocapr... 17652888 - Considerable disagreement among definitions of metabolic syndrome for japanese. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-5-17 |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: - ISSN: 1365-2036 ISO Abbreviation: - Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-5-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, London, UK. UCL Cancer Institute, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimising the care of patients with cirrhosis and gastrointestinal haemorrhage: a quality improveme...
Next Document: Validation of the non-alcoholic fatty liver disease activity score.